BR112019020386A2 - vacinas de peptídeos de pd-1 humana e usos das mesmas - Google Patents

vacinas de peptídeos de pd-1 humana e usos das mesmas Download PDF

Info

Publication number
BR112019020386A2
BR112019020386A2 BR112019020386-9A BR112019020386A BR112019020386A2 BR 112019020386 A2 BR112019020386 A2 BR 112019020386A2 BR 112019020386 A BR112019020386 A BR 112019020386A BR 112019020386 A2 BR112019020386 A2 BR 112019020386A2
Authority
BR
Brazil
Prior art keywords
human
peptide vaccines
peptides
antibodies
alzheimer
Prior art date
Application number
BR112019020386-9A
Other languages
English (en)
Portuguese (pt)
Inventor
T.P. Kaumaya Pravin
BEKAII-SAAB Tanios
Original Assignee
Ohio State Innovation Foundation
Mayo Foundation For Medical Education And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation, Mayo Foundation For Medical Education And Research filed Critical Ohio State Innovation Foundation
Publication of BR112019020386A2 publication Critical patent/BR112019020386A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR112019020386-9A 2017-03-28 2018-03-28 vacinas de peptídeos de pd-1 humana e usos das mesmas BR112019020386A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477895P 2017-03-28 2017-03-28
US62/477,895 2017-03-28
PCT/US2018/024831 WO2018183488A1 (en) 2017-03-28 2018-03-28 Human pd1 peptide vaccines and uses thereof

Publications (1)

Publication Number Publication Date
BR112019020386A2 true BR112019020386A2 (pt) 2020-06-09

Family

ID=63678120

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019020386-9A BR112019020386A2 (pt) 2017-03-28 2018-03-28 vacinas de peptídeos de pd-1 humana e usos das mesmas

Country Status (11)

Country Link
US (1) US11684660B2 (enExample)
EP (1) EP3600398B1 (enExample)
JP (1) JP7346302B2 (enExample)
KR (1) KR102653567B1 (enExample)
CN (2) CN118909082A (enExample)
AU (2) AU2018243920B2 (enExample)
BR (1) BR112019020386A2 (enExample)
CA (1) CA3058393A1 (enExample)
ES (1) ES2963635T3 (enExample)
RU (1) RU2019131252A (enExample)
WO (1) WO2018183488A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019153042A1 (en) * 2018-02-07 2019-08-15 Imugene Limited A vaccine composition and uses thereof
JP7304421B2 (ja) * 2018-10-05 2023-07-06 アールエヌエージーン インコーポレイテッド 標的細胞特異的に結合して多重免疫機能が強化されたキメラ抗原及びこの用途
BR112022005044A2 (pt) * 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
US20260007730A1 (en) * 2022-04-21 2026-01-08 Ohio State Innovation Foundation Human ctla-4 peptide vaccines and uses thereof
WO2024211745A1 (en) * 2023-04-05 2024-10-10 Ohio State Innovation Foundation Human pd1, pd-l1, and ctla-4 combination peptide vaccines and uses thereof
CN119019569B (zh) * 2024-08-19 2025-10-24 中国人民解放军陆军军医大学 一种可定向增强胸腺新生t细胞杀伤乳腺癌的多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
WO1997038011A1 (en) * 1996-04-03 1997-10-16 Pepresearch A/S Non-dendritic backbone peptide carrier
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
EP1651258B1 (en) * 2003-07-30 2014-03-19 Vaccine Research Institute of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
GB0400440D0 (en) * 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
AU2006261342B2 (en) * 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
AU2009274568A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
US20100234283A1 (en) * 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
NZ713461A (en) * 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
IN2014KN00920A (enExample) * 2012-06-21 2015-10-09 Compugen Ltd
US9381244B2 (en) * 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
CN105377897A (zh) * 2013-05-03 2016-03-02 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
PT3177640T (pt) * 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
DK3237446T3 (en) * 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer

Also Published As

Publication number Publication date
AU2018243920A1 (en) 2019-10-31
US11684660B2 (en) 2023-06-27
CA3058393A1 (en) 2018-10-04
KR20190137826A (ko) 2019-12-11
US20200197498A1 (en) 2020-06-25
RU2019131252A (ru) 2021-04-28
AU2025201760A1 (en) 2025-05-22
CN118909082A (zh) 2024-11-08
ES2963635T3 (es) 2024-04-01
JP2020512375A (ja) 2020-04-23
RU2019131252A3 (enExample) 2021-06-01
CN110636855B (zh) 2024-08-09
EP3600398A1 (en) 2020-02-05
KR102653567B1 (ko) 2024-04-02
EP3600398B1 (en) 2023-09-13
JP7346302B2 (ja) 2023-09-19
WO2018183488A1 (en) 2018-10-04
CN110636855A (zh) 2019-12-31
AU2018243920B2 (en) 2024-12-12
EP3600398A4 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
BR112019020386A2 (pt) vacinas de peptídeos de pd-1 humana e usos das mesmas
CO2019012998A2 (es) Proteínas de unión a antígenos trem2 y usos de estas
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
GEAP202114720A (en) Constructs having a sirp-alpha domain or variant thereof
CL2019001756A1 (es) Anticuerpos anti-cd73 y usos de los mismos.
ECSP19026304A (es) Anticuerpos de unión a cd3
DOP2018000146A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
MX2018016404A (es) Anticuerpos de union a cd3.
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
EA201991005A1 (ru) Антитела и полипептиды, направленные против cd127
GEAP202115055A (en) Anti-cd27 antibodies
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
AR103867A1 (es) Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos
EA201691836A1 (ru) Антитела к mcam и соответствующие способы их применения
GEAP202114964A (en) ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF
BR112016027595A8 (pt) produtos de peptídeos, composição farmacêutica compreendendo um produto de peptídeo, uso de um produto de peptídeo e método para produzir um produto de peptídeo
MX389320B (es) Anticuerpos anti-tnfrsf25
WO2015161267A3 (en) Humanized and chimeric monoclonal antibodies to cd99
MX390418B (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso.
BR112022005044A2 (pt) Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]